289 related articles for article (PubMed ID: 28533163)
1. GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors.
Mullier B; Wolff C; Sands ZA; Ghisdal P; Muglia P; Kaminski RM; André VM
Neuropharmacology; 2017 Sep; 123():322-331. PubMed ID: 28533163
[TBL] [Abstract][Full Text] [Related]
2. Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist.
McKay S; Griffiths NH; Butters PA; Thubron EB; Hardingham GE; Wyllie DJ
Br J Pharmacol; 2012 Jun; 166(3):924-37. PubMed ID: 22022974
[TBL] [Abstract][Full Text] [Related]
3. Deconstruction - Reconstruction: Analysis of the Crucial Structural Elements of GluN2B-Selective, Negative Allosteric NMDA Receptor Modulators with 3-Benzazepine Scaffold.
Ritter N; Korff M; Markus A; Schepmann D; Seebohm G; Schreiber JA; Wünsch B
Cell Physiol Biochem; 2021 Mar; 55(S3):1-13. PubMed ID: 33656308
[TBL] [Abstract][Full Text] [Related]
4. Effects of GluN2A and GluN2B gain-of-function epilepsy mutations on synaptic currents mediated by diheteromeric and triheteromeric NMDA receptors.
Chen X; Keramidas A; Harvey RJ; Lynch JW
Neurobiol Dis; 2020 Jul; 140():104850. PubMed ID: 32247039
[TBL] [Abstract][Full Text] [Related]
5. Opportunities for Precision Treatment of
Han W; Yuan H; Allen JP; Kim S; Shaulsky GH; Perszyk RE; Traynelis SF; Myers SJ
J Pharmacol Exp Ther; 2022 Apr; 381(1):54-66. PubMed ID: 35110392
[TBL] [Abstract][Full Text] [Related]
6. Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndrome.
Auvin S; Dozières-Puyravel B; Avbersek A; Sciberras D; Collier J; Leclercq K; Mares P; Kaminski RM; Muglia P
Ann Clin Transl Neurol; 2020 Mar; 7(3):343-352. PubMed ID: 32106360
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Novel PET Tracer [
van der Aart J; Yaqub M; Kooijman EJM; Bakker J; Langermans JAM; Schuit RC; Hofman MBM; Christiaans JAM; Lammertsma AA; Windhorst AD; van Berckel BNM
Mol Imaging Biol; 2019 Aug; 21(4):676-685. PubMed ID: 30306318
[TBL] [Abstract][Full Text] [Related]
8. Functional and pharmacological properties of triheteromeric GluN1/2B/2D NMDA receptors.
Yi F; Bhattacharya S; Thompson CM; Traynelis SF; Hansen KB
J Physiol; 2019 Nov; 597(22):5495-5514. PubMed ID: 31541561
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice.
Fernandes A; Wojcik T; Baireddy P; Pieschl R; Newton A; Tian Y; Hong Y; Bristow L; Li YW
Eur J Pharmacol; 2015 Nov; 766():1-8. PubMed ID: 26325093
[TBL] [Abstract][Full Text] [Related]
10. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits.
Chatterton JE; Awobuluyi M; Premkumar LS; Takahashi H; Talantova M; Shin Y; Cui J; Tu S; Sevarino KA; Nakanishi N; Tong G; Lipton SA; Zhang D
Nature; 2002 Feb; 415(6873):793-8. PubMed ID: 11823786
[TBL] [Abstract][Full Text] [Related]
11. Point mutations identify the glutamate binding pocket of the N-methyl-D-aspartate receptor as major site of conantokin-G inhibition.
Wittekindt B; Malany S; Schemm R; Otvos L; Maccecchini ML; Laube B; Betz H
Neuropharmacology; 2001 Nov; 41(6):753-61. PubMed ID: 11640930
[TBL] [Abstract][Full Text] [Related]
12. Synaptic NMDA receptors in basolateral amygdala principal neurons are triheteromeric proteins: physiological role of GluN2B subunits.
Delaney AJ; Sedlak PL; Autuori E; Power JM; Sah P
J Neurophysiol; 2013 Mar; 109(5):1391-402. PubMed ID: 23221411
[TBL] [Abstract][Full Text] [Related]
13. GRIN1 variants associated with neurodevelopmental disorders reveal channel gating pathomechanisms.
Ragnarsson L; Zhang Z; Das SS; Tran P; Andersson Å; des Portes V; Desmettre Altuzarra C; Remerand G; Labalme A; Chatron N; Sanlaville D; Lesca G; Anggono V; Vetter I; Keramidas A
Epilepsia; 2023 Dec; 64(12):3377-3388. PubMed ID: 37734923
[TBL] [Abstract][Full Text] [Related]
14. Disease-associated missense mutations in GluN2B subunit alter NMDA receptor ligand binding and ion channel properties.
Fedele L; Newcombe J; Topf M; Gibb A; Harvey RJ; Smart TG
Nat Commun; 2018 Mar; 9(1):957. PubMed ID: 29511171
[TBL] [Abstract][Full Text] [Related]
15. The GluN2B-Glu413Gly NMDA receptor variant arising from a de novo GRIN2B mutation promotes ligand-unbinding and domain opening.
Wells G; Yuan H; McDaniel MJ; Kusumoto H; Snyder JP; Liotta DC; Traynelis SF
Proteins; 2018 Dec; 86(12):1265-1276. PubMed ID: 30168177
[TBL] [Abstract][Full Text] [Related]
16. Quinoxaline derivatives: structure-activity relationships and physiological implications of inhibition of N-methyl-D-aspartate and non-N-methyl-D-aspartate receptor-mediated currents and synaptic potentials.
Randle JC; Guet T; Bobichon C; Moreau C; Curutchet P; Lambolez B; de Carvalho LP; Cordi A; Lepagnol JM
Mol Pharmacol; 1992 Feb; 41(2):337-45. PubMed ID: 1371583
[TBL] [Abstract][Full Text] [Related]
17. Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists.
Hansen KB; Mullasseril P; Dawit S; Kurtkaya NL; Yuan H; Vance KM; Orr AG; Kvist T; Ogden KK; Le P; Vellano KM; Lewis I; Kurtkaya S; Du Y; Qui M; Murphy TJ; Snyder JP; Bräuner-Osborne H; Traynelis SF
J Pharmacol Exp Ther; 2010 Jun; 333(3):650-62. PubMed ID: 20197375
[TBL] [Abstract][Full Text] [Related]
18. Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action.
Kleckner NW; Glazewski JC; Chen CC; Moscrip TD
J Pharmacol Exp Ther; 1999 May; 289(2):886-94. PubMed ID: 10215667
[TBL] [Abstract][Full Text] [Related]
19. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity.
Ballard TM; Pauly-Evers M; Higgins GA; Ouagazzal AM; Mutel V; Borroni E; Kemp JA; Bluethmann H; Kew JN
J Neurosci; 2002 Aug; 22(15):6713-23. PubMed ID: 12151550
[TBL] [Abstract][Full Text] [Related]
20. Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors.
Hansen KB; Ogden KK; Yuan H; Traynelis SF
Neuron; 2014 Mar; 81(5):1084-1096. PubMed ID: 24607230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
